Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2025-01-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. It details a change in share ownership (specifically a disposal of shares) by Humedix Co., Ltd. in Ensol Biosciences. This type of filing is a standard regulatory requirement for major shareholders to disclose changes in their holdings, which falls under the 'Major Shareholding Notification' category.
2025-01-08 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details a change in share ownership (5.04%) by an individual (Hyung Inwoo) in Ensol Biosciences. This type of filing is a standard regulatory requirement for significant shareholding notifications, which falls under the 'Major Shareholding Notification' category.
2025-01-06 Korean
기타주요경영사항(자율공시) (라이센스계약 해지)
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure from Ensol Biosciences regarding the termination of a license agreement with Humedix. It details the contract, the financial milestones, and the reason for termination. Since it is a specific corporate event disclosure that does not fit into financial reporting, M&A, or other specific categories, it falls under the general regulatory filing category.
2025-01-03 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date for the purpose of holding an upcoming Annual General Meeting (AGM). It specifies the record date (2024-12-31) and the reason (holding the 24th Annual General Meeting). Since it is a regulatory announcement regarding meeting preparations rather than the meeting materials themselves or a financial report, it falls under the general regulatory filing category.
2024-12-16 Korean
주주총회소집결의
AGM Information Classification · 95% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for Ensol Biosciences, detailing the date, location, and agenda items (specifically a third-party capital increase). In the context of corporate filings, documents that solicit votes or provide notice for shareholder meetings are classified as Proxy Solicitation & Information Statements.
2024-12-12 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure of corporate action, it fits best under the RNS category.
2024-12-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.